Hmmm just my opinion here so they lower the offering, so did the ones with deep pockets convince the doctor to lower the offering and by doing so they will buy into the offering as soon as they get the results from the test.
Which we all know will meet and or past the expectations of the fda. My opinion the fda likes the results of the test it will be a thumbs up for ide approval.
So a possibility of them closing out the offering before ide approval is pretty high and would give them the cash for human testing at least for phase 1.
My guess with the satisfactory test results the share price will start moving up before ide approval.
Not knowing the cost of human testing which I wouldn’t think it would be all that much considering that the testing length per phase will possibly be reduced considering the life expectancy of the gel and Y90 in the body.
News 
Market Data 
Discover 
